Stock Events

Medicenna Therapeutics 

C$1.73
18
-C$0.11-5.98% Wednesday 19:57

Statistics

Day High
1.89
Day Low
1.72
52W High
2.1
52W Low
0.22
Volume
158,701
Avg. Volume
140,200
Mkt Cap
136.49M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

13NovConfirmed
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Q2 2023
Q3 2023
-0.13
-0.09
-0.05
-0.01
Expected EPS
-0.05
Actual EPS
-0.04

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MDNA.TO. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

About

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.
Show more...
CEO
Dr. Fahar Merchant Ph.D.
Employees
16
Country
CA
ISIN
CA58490H1073

Listings